SCHEMBL3378181

SCHEMBL3378181

CCNC(=O)c1cccc(O)c1NS(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
CXCR2 P25025 1/20 0.43
KDM4E B2RXH2 8/20 0.43
ALDH1A1 P00352 6/20 0.43
HSD17B10 Q99714 4/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALOX5 P09917 1/20 0.42
NAAA Q02083 1/20 0.41
RCE1 Q9Y256 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.40
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3382919 0.89 NAAA (0.49) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL3383600 0.82 HPGD (0.54) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL9132045 0.77 ALOX5 (0.66) CA1CA9CXCR2KDM4EKMT2A
SCHEMBL7669371 0.77 EP300 (0.48) CA1CA9ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL1797745 0.76 CA1 (0.68) CA1CA9KDM4EALDH1A1HSD17B10
SCHEMBL12677093 0.74 CA1 (0.50) CA1CA9CXCR2KDM4EHSD17B10
SCHEMBL31483721 0.71 HTT (0.64) CA1CA9CXCR2ALDH1A1HPGD
SCHEMBL26417076 0.71 HTT (0.64) CA1CA9CXCR2ALDH1A1HPGD
SCHEMBL3142355 0.70 HCRTR1 (0.49) CA1CA9CXCR2KDM4ESMN1; SMN2
SCHEMBL13477779 0.69 ALDH1A1 (0.58) CXCR2KDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CA1 582/4885CA9 3965/4885CXCR2 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.